Time course of treatment-emergent adverse events (teaes) in the randomized, controlled phase 3 resorce trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment

This article has no abstract
Epistemonikos ID: b06a733c78d0db5e2665cd1a5258ac2b1c7d68ea
First added on: Feb 08, 2025